Last month, MDClone participated in the annual ISPOR conference for the first time as a corporate exhibitor. ISPOR, the professional society for Health Economics and Outcomes Research (HEOR), held this year’s conference May 15–18, 2022 in National Harbor, Maryland, USA.

Featuring speakers from medical institutions, universities, pharmaceutical companies, and life science organizations, the ISPOR 2022 conference offers opportunities for researchers and clinicians to present their work and exchange ideas at a meeting-of-the-minds scientific venue. This year’s conference was a hybrid event, featuring both in-person and virtual talks.

The common theme throughout ISPOR 2022 was the need for healthcare data and how to better access them.

Fortunately, MDClone offers a fundamentally different approach to unlocking these data. MDClone allows clinicians, researchers, life science companies, and governmental agencies to generate and access synthetic data, which are novel data created to reflect the statistical properties of real patient data without containing information that identifies real patients. Additionally, the MDClone ADAMS Platform puts the power of discovery in the hands of non-technical specialists with its self-service analytics tools, rapidly decreasing the time to insight to improve the health of patients worldwide. Data are stored in a centralized repository called a data lake, representing diverse populations with significant granularity.

“The MDClone big data solution, with its unique synthetic data capabilities, enables healthcare institutions to make their datasets globally available outside of their organizations.”

— Noa Zamstein, PhD, Director of the MDClone Research and Data Science Center

“Healthcare institutions could partner with third parties, such as life science companies, to dramatically transform the [healthcare] landscape,” said Zamstein.

The conference was attended by Dr. Zamstein; Jon D. Morrow, MD, Senior VP of Medical Affairs & Informatics at MDClone; Robi Wartenfeld, MD, Chief Medical Officer and VP of Products at MDClone; Daniel Blumenthal, VP of Strategy at MDClone; and Jim Sides, Director of Business Development at MDClone.

At the event, Dr. Morrow represented MDClone on the ISPOR Institutional Council, which serves to support and promote ISPOR’s mission as a professional and educational society. He was also part of the Exploratory Real-World Evidence (RWE) Study Working Group at the conference, a group of industry-leading RWE experts focused on exploring methodologies to enable the full integration of RWE into clinical and pharmacologic research.

Additionally, as part of the pre-program for ISPOR, MDClone and ISPOR launched the first-ever webinar on synthetic data for real-world evidence. The webinar, titled, “The Convergence of Synthetic Data and Self-Service Analytics to Create a New RWE Model,” targeted life science organizations, biotechnology companies, and pharmaceutical companies and featured speakers from MDClone, ISPOR, and Vifor Pharma.

Next year at ISPOR 2023 in Boston, Massachusetts, MDClone plans to present content related to its upcoming life science partnerships and further outline the ways in which life sciences and pharmaceutical companies can get maximal access to healthcare data for their research.

“Synthetic data has the potential to offer another excellent resource for HEOR.”

— Richard Willke, PhD, Chief Science Officer at ISPOR

“Depending on how limited access to real-world data is, the one potential for synthetic data is that it can be resident at a company or licensed by a company to provide easy access to data for exploratory analysis and modeling, and those are the kind of things we need to do our work,” said Willke.